文献速递衰弱、肌少症与跌倒老年慢病共病管理

高龄房颤患者药物节律控制策略与结局:意大利START注册研究分析

Pharmacological rhythm control strategy and outcomes in the oldest atrial fibrillation patients: an analysis of the nationwide Italian START registry.
PubMed 文献 · Age Ageing · 2026-01-01

基于意大利全国START注册研究,纳入4244例年龄≥80岁房颤患者,分析抗心律失常药物(AADs)使用与临床结局的关系。中位随访502天,1c类AADs使用与较低合并症负担相关,胺碘酮使用与冠心病和衰弱标志物相关;多变量调整后,AADs与全因死亡或心血管事件均无独立关联。提示高龄房颤患者药物节律控制或应限于特定病例。

要点

  • 高龄房颤患者中AADs使用率15.8%,胺碘酮占10.9%,1c类AADs占4.9%。
  • 1c类AADs使用者更年轻、合并症更少、功能和社交状态更好。
  • 多变量调整后,AADs与全因死亡或心血管事件无独立关联。

核心结论

  • 在高龄房颤患者中,AADs使用受合并症负担和衰弱相关特征影响。
  • AADs与死亡或心血管事件无独立关联,药物节律控制或应保留给特定病例。

研究设计与样本

  • 基于意大利全国START注册研究的回顾性分析,纳入年龄≥80岁房颤患者4244例(女性54.9%),平均年龄84.8±3.8岁。
  • 患者分为三组:未用AADs(n=3573)、1c类AADs(n=207)和胺碘酮(n=464)。
  • 采用多变量logistic回归评估AADs相关因素,Cox比例风险模型评估全因死亡,Fine-Gray竞争风险模型分析心血管事件(CVEs)。

主要发现

  • AADs处方于671例患者(15.8%),其中胺碘酮464例(10.9%),1c类AADs 207例(4.9%)。
  • 1c类AADs使用与较年轻年龄和较少合并症相关,包括糖尿病、心力衰竭、慢性阻塞性肺疾病/阻塞性睡眠呼吸暂停患病率较低,功能和社交状态更好。
  • 胺碘酮使用与冠心病和衰弱标志物相关。
  • 中位随访502天(四分位距362-857天)期间,发生492例死亡和548例CVEs。
  • 未调整分析中,1c类AADs与较低全因死亡和CVEs相关,但多变量调整后不再显著;胺碘酮在未调整和调整分析中均与临床结局无关。

临床怎么用

  • 在高龄房颤患者中处方AADs时,应评估合并症负担和衰弱相关特征。
  • 药物节律控制可能仅适用于经过选择的特定高龄房颤患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on antiarrhythmic drugs (AADs) in the oldest atrial fibrillation (AF) patients is limited. We investigated clinical characteristics and outcomes associated with AADs use in this population. METHODS: The oldest (age ≥ 80 years) AF patients from the nationwide START registry were included. Patients were divided into three groups: no AADs (n = 3573), class 1c-AADs (n = 207) and Amiodarone (n = 464). Factors associated with AADs were evaluated using multivariable logistic regression models. The associations between AADs and all-cause mortality were assessed using Cox proportional hazards models and cardiovascular events (CVEs) were analysed using Fine-Gray competing risk models. RESULTS: Among 4244 patients (54.9% women), the mean age was 84.8 ± 3.8 years. AADs were prescribed in 671 patients (15.8%), including amiodarone in 464 (10.9%) and 1c-AADs in 207 (4.9%). 1c-AADs use was associated with younger age and fewer comorbidities, including lower prevalence of diabetes, heart failure, chronic obstructive pulmonary disease/obstructive sleep apnoea and better functional and social status. Amiodarone use was associated with coronary artery disease and markers of frailty. Over a median follow-up of 502 (interquartile range 362-857) days, 492 deaths and 548 CVEs occurred. In unadjusted analyses, 1c-AADs were associated with lower all-cause mortality and CVEs; however, these associations were no longer significant after multivariable adjustment. Amiodarone use was not associated with clinical outcomes in either unadjusted or adjusted analyses. CONCLUSION: In the oldest AF patients, AADs use is influenced by comorbidity burden and frailty-related characteristics. AADs were not independently associated with mortality or CVEs, suggesting that pharmacological rhythm control may be reserved for selected cases in this population.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Menichelli D, Gazzaniga G, Poli D, et al. Pharmacological rhythm control strategy and outcomes in the oldest atrial fibrillation patients: an analysis of the nationwide Italian START registry. Age Ageing. 2026. PMID: 42202280. doi:10.1093/ageing/afag157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。